These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10946217)

  • 1. Bioactive products of phospholipid oxidation: isolation, identification, measurement and activities.
    Subbanagounder G; Watson AD; Berliner JA
    Free Radic Biol Med; 2000 Jun; 28(12):1751-61. PubMed ID: 10946217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo.
    Watson AD; Leitinger N; Navab M; Faull KF; Hörkkö S; Witztum JL; Palinski W; Schwenke D; Salomon RG; Sha W; Subbanagounder G; Fogelman AM; Berliner JA
    J Biol Chem; 1997 May; 272(21):13597-607. PubMed ID: 9153208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation.
    Friedman P; Horkko S; Steinberg D; Witztum JL; Dennis EA
    J Biol Chem; 2002 Mar; 277(9):7010-20. PubMed ID: 11744722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position.
    Subbanagounder G; Leitinger N; Schwenke DC; Wong JW; Lee H; Rizza C; Watson AD; Faull KF; Fogelman AM; Berliner JA
    Arterioscler Thromb Vasc Biol; 2000 Oct; 20(10):2248-54. PubMed ID: 11031211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids.
    Leitinger N; Watson AD; Hama SY; Ivandic B; Qiao JH; Huber J; Faull KF; Grass DS; Navab M; Fogelman AM; de Beer FC; Lusis AJ; Berliner JA
    Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1291-8. PubMed ID: 10323782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural identification of a novel pro-inflammatory epoxyisoprostane phospholipid in mildly oxidized low density lipoprotein.
    Watson AD; Subbanagounder G; Welsbie DS; Faull KF; Navab M; Jung ME; Fogelman AM; Berliner JA
    J Biol Chem; 1999 Aug; 274(35):24787-98. PubMed ID: 10455151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis : in vitro and In vivo inhibition by WEB 2086.
    Subbanagounder G; Leitinger N; Shih PT; Faull KF; Berliner JA
    Circ Res; 1999 Aug; 85(4):311-8. PubMed ID: 10455059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for a role of phospholipid oxidation products in atherogenesis.
    Berliner JA; Subbanagounder G; Leitinger N; Watson AD; Vora D
    Trends Cardiovasc Med; 2001; 11(3-4):142-7. PubMed ID: 11686004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phospholipid hydrolysis of mildly oxidized LDL reduces their cytotoxicity to cultured endothelial cells. Potential protective role against atherogenesis.
    Schmitt A; Nègre-Salvayre A; Troly M; Valdiguié P; Salvayre R
    Biochim Biophys Acta; 1995 Jun; 1256(3):284-92. PubMed ID: 7786889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioactive phospholipid oxidation products.
    Marathe GK; Harrison KA; Murphy RC; Prescott SM; Zimmerman GA; McIntyre TM
    Free Radic Biol Med; 2000 Jun; 28(12):1762-70. PubMed ID: 10946218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidized LDL contains inflammatory PAF-like phospholipids.
    Marathe GK; Prescott SM; Zimmerman GA; McIntyre TM
    Trends Cardiovasc Med; 2001; 11(3-4):139-42. PubMed ID: 11686003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein oxidation and atherosclerosis.
    Young IS; McEneny J
    Biochem Soc Trans; 2001 May; 29(Pt 2):358-62. PubMed ID: 11356183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques.
    Leeuwenburgh C; Rasmussen JE; Hsu FF; Mueller DM; Pennathur S; Heinecke JW
    J Biol Chem; 1997 Feb; 272(6):3520-6. PubMed ID: 9013599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidation products of phospholipid-containing delta-9 fatty acids specifically impair the activity of tissue factor pathway inhibitor.
    Hiraishi S; Horie S; Seyama Y
    Biochem Biophys Res Commun; 2002 Nov; 298(4):468-73. PubMed ID: 12408975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL.
    Navab M; Ananthramaiah GM; Reddy ST; Van Lenten BJ; Ansell BJ; Fonarow GC; Vahabzadeh K; Hama S; Hough G; Kamranpour N; Berliner JA; Lusis AJ; Fogelman AM
    J Lipid Res; 2004 Jun; 45(6):993-1007. PubMed ID: 15060092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 7 beta-hydroperoxycholest-5-en-3 beta-ol, a component of human atherosclerotic lesions, is the primary cytotoxin of oxidized human low density lipoprotein.
    Chisolm GM; Ma G; Irwin KC; Martin LL; Gunderson KG; Linberg LF; Morel DW; DiCorleto PE
    Proc Natl Acad Sci U S A; 1994 Nov; 91(24):11452-6. PubMed ID: 7972083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p-hydroxyphenylacetaldehyde, an aldehyde generated by myeloperoxidase, modifies phospholipid amino groups of low density lipoprotein in human atherosclerotic intima.
    Heller JI; Crowley JR; Hazen SL; Salvay DM; Wagner P; Pennathur S; Heinecke JW
    J Biol Chem; 2000 Apr; 275(14):9957-62. PubMed ID: 10744670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin E oxidation in human atherosclerotic lesions.
    Terentis AC; Thomas SR; Burr JA; Liebler DC; Stocker R
    Circ Res; 2002 Feb; 90(3):333-9. PubMed ID: 11861423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phospholipids and oxophospholipids in atherosclerotic plaques at different stages of plaque development.
    Ravandi A; Babaei S; Leung R; Monge JC; Hoppe G; Hoff H; Kamido H; Kuksis A
    Lipids; 2004 Feb; 39(2):97-109. PubMed ID: 15134136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidized phospholipids in oxidized low-density lipoprotein reduce the activity of tissue factor pathway inhibitor through association with its carboxy-terminal region.
    Ohkura N; Hiraishi S; Itabe H; Hamuro T; Kamikubo Y; Takano T; Matsuda J; Horie S
    Antioxid Redox Signal; 2004 Aug; 6(4):705-12. PubMed ID: 15242551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.